Metallocene-Boronic Acid-Containing Compounds and Copolymers as Antimicrobial Agents


Reference #: 01254

The University of South Carolina is offering licensing opportunities for using antibiotics-loaded boronic-containing cationic metallocene polymer systems that can kill multidrug resistant (MDR) bacteria.



Bacterial infections have become one of the most urgent global health threats, leading to increased healthcare costs, destruction of local tissues, patient disability, morbidity, and even death. If no effective strategy is undertaken to prevent and treat bacterial infections, they could claim 10 million lives and cost up to 100 trillion dollars globally by 2050. Commonly used antibiotics such as penicillin and methicillin have a diminished antimicrobial efficacy, and numerous bacterial pathogens accumulate multidrug resistance (MDR). Multidrug-resistant Gram-negative bacteria are posing increasingly alarming threats, making many last-resort antibiotics futile for treatments. Compared to therapies against Gram-positive strains, a recent analysis showed very few antibiotics in development could be promising for fighting these life-threatening Gram-negative bacterial infections. Due to the nature of double cell membranes as their intrinsic defense, it is very challenging for antibiotics to not only inhibit critical bacterial processes, but also penetrate cells via two membrane barriers and escape efflux pumps. In many cases, these agents can cross the outer membrane, but stop short of penetrating the cytoplasmic membrane. Meanwhile, one must overcome the demanding efflux pumps even after the penetration of two membranes. With the frequency of MDR increasing at an alarming rate, it is very urgent to develop new approaches for effective antimicrobial agents. It would be most desirable to afford multiple pathogen-specific therapeutics, particularly targeting Gram-negative bacteria.


Invention Description:

The subject invention are antibiotics loaded boronic-containing cationic metallocene polymer systems that can kill multidrug resistant bacteria including, but not limiting to, Staphylococcus, Enterobacteriaceae, Haemophilus influenzae, Neisseria gonorrhoeae, Klebsiella pneumoniae, Citrobacter, Acinetobacter, Morganella, and Pseudomonas aeruginosa.


Potential Applications:

Current antibiotics, especially beta-lactam based drugs, cannot kill most superbugs such as Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE). This invention provides a new formulation to address this problem.


Advantages and Benefits:

This invention contains a completely different mechanism for killing superbugs. It is therefore more efficient than most other formulations.


Patent Information:
For Information, Contact:
Technology Commercialization
University of South Carolina
Chuanbing Tang
Peng Yang
© 2019. All Rights Reserved. Powered by Inteum